✦ LIBER ✦

The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions

✍ Scribed by Donald S. Silverberg; Dov Wexler; Adrian Iaina; Doron Schwartz

Publisher: Springer
Year: 2009
Tongue: English
Weight: 166 KB
Volume: 13
Category: Article
ISSN: 1342-1751
DOI: 10.1007/s10157-008-0074-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact of heart failure on the incidence

Impact of heart failure on the incidence of contrast-induced nephropathy in patients with chronic kidney disease

✍ Jordan L. Rosenstock; Emmanuelle Gilles; Ari B. Geller; Georgia Panagopoulos; St 📂 Article 📅 2010 🏛 Springer Netherlands 🌐 English ⚖ 163 KB

Measurement of adenylate cyclase activit

Measurement of adenylate cyclase activity in the right ventricular endomyocardial biopsy samples from patients with chronic congestive heart failure

✍ Atsushi Sugiyama; Tetsuro Shirai; Kiyoshi Inoue; Keith G. Lurie; Keitaro Hashimo 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 2 views

The vasopressor system in patients with

The vasopressor system in patients with heart failure due to idiopathic dilated cardiomyopathy-influence of the clinical stage of disease and of chronic drug treatment

✍ V. Mitrovic; J. Thormann; P. Kornecki; M. Volz; H. Neuss; M. Schlepper 📂 Article 📅 1989 🏛 Springer US 🌐 English ⚖ 669 KB

Cenderitide (CD-NP), a novel peptide des

Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure

✍ Lisa C Costello-Boerrigter; John A Schirger; Wayne L Miller; Guido Boerrigter; H 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 135 KB

Costello-Boerrigter et al.: Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure.